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ABSTRACT
An association between impaired fetal growth and the postnatal
development of obesity has been established. Here, by comparing
adipocytes differentiated frommesenchymal stem cells (MSCs) taken
from the umbilical cord and derived from normal and growth-restricted
neonates, we identified the transcription factor SOX6 as highly
expressed only in growth-restricted individuals. We found that
SOX6 regulates adipogenesis in vertebrate species by activating
adipogenic regulators including PPARγ, C/EBPα and MEST. We
further show that SOX6 interacts with β-catenin in adipocytes,
suggesting an inhibition of WNT/β-catenin signaling, thereby
promoting adipogenesis. The upstream regulatory region of the
MEST gene in MSCs from growth-restricted subjects harbors
hypomethylated CpGs next to SOX6 binding motifs, and we found
that SOX6 binding is impaired by adjacent CpG methylation. In
summary, we report that SOX6 is a novel regulator of adipogenesis
synergizing with epigenetic mechanisms.
KEY WORDS: Developmental origins, Epigenetics, Fetal growth
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INTRODUCTION
Obesity is becoming increasingly prevalent and contributes to
morbidity and mortality worldwide (Ng et al., 2014; Bhurosy and
Jeewon, 2014). Although there is little doubt that it can result from
adult lifestyle factors, there is increasing evidence for developmental
factors playing an important role and these appear to operate through
epigenetic pathways (van Dijk et al., 2015). Indeed, there is
compelling evidence to support the concept that the origins of
obesity often begin in utero (Desai et al., 2005; de Rooij et al., 2007)
and impaired fetal growth has been linked to the development of
obesity and metabolic diseases in adult life (Godfrey and Barker,
2001; Kensara et al., 2006). The role of low birth weight in the
development of human adult non-communicable diseases has been
described (Lackland et al., 2000; Tian et al., 2006). In particular,
infants with low birth weight and fetal growth restriction combined
with accelerated catch-up in the first few years of life are at higher risk
of developing obesity (Khandelwal et al., 2014; Varvarigou, 2010).
The mechanistic pathway by which impaired intrauterine
conditions induce later sensitivity to an obesogenic environment has
been extensively reviewed (Hanson andGluckman, 2014) and there is
clinical evidence suggesting that epigenetic mechanisms are involved
(Godfrey et al., 2011). To explore molecular mechanisms that might
be important in this relationship, we previously reported the use of
multipotentmesenchymal stem cells (MSCs) from theWharton’s jelly
of umbilical cord (UC) tissue to generate primary UC-MSC isolates
from small for gestational age (SGA) and normal neonates (Sukarieh
et al., 2014). Chromatin immunoprecipitation-sequencing (ChIP-seq)
studies from adipocytes differentiated fromMSCs revealed candidate
genes that were found to be associated with histone hyperacetylation
and increased gene expression in the SGA group (Joseph et al., 2015).
One gene of uncertain functional importance found in that study is
SOX6 [SRY (sex determining regionY)-box 6]. Here, we describe the
effects of SOX6 on adipogenesis and demonstrate putative molecular
mechanisms by showing that SOX6 regulates the expression of key
adipogenic regulators and synergizes with epigenetic pathways
involving MEST (mesoderm specific transcript), which is known to
be associated with adipocyte size (Takahashi et al., 2005) and adipose
tissue expansion but with as yet unknown biochemical functions
(Voigt et al., 2015). Epigenetic changes within the MEST promoter
have previously been associated with maternal stress leading to
adverse birth outcomes (Vidal et al., 2014). Our results show that
epigenetic properties of the MEST gene upstream regulatory region
synergizewith SOX6 function in positively regulating adipogenesis in
MSCs isolated from SGA individuals.
RESULTS
SOX6 is highly expressed in MSC-derived adipocytes from
SGA neonates
In our previous study, histone ChIP-seq using preadipocytes (cycle
0), intermediate adipocytes (cycle 3) and mature differentiated
adipocytes (cycle 6) from two representative cell lines of SGA
(MSC-01) and control group (MSC-44) of human neonates revealed
notably different enrichment of H3K27 acetylation sites in
adipocytes derived from the SGA background (Joseph et al.,
2015). SOX6 was among the most significant genes with promoter-
associated H3K27 acetylation along with lower levels of H3K27
trimethylation in adipocytes derived from the MSC-01 SGA
compared with the MSC-44 control isolate (Fig. 1A).
We evaluated the expression pattern of SOX6 in adipocytes
derived from both MSC-01 and MSC-44 (Fig. 1B), as well as
adipocytes derived from an extended larger group of primary SGAReceived 6 October 2015; Accepted 5 February 2016
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and control MSC isolates (Fig. 1C, Table S2). SOX6 gene
expression levels were significantly higher in adipocytes from the
SGA background. Similar observations were made for known
adipogenic genes, such as those encoding PPARγ, C/EBPα, FABP4
and FASN (Fig. S1C), in line with our published observations of a
higher adipogenic potential for differentiated MSCs derived from
the SGA group (Joseph et al., 2015). Western blots showing the
protein levels of SOX6 in the adipocytes (Fig. 1D) confirmed our
qRT-PCR findings and correlated well with the transcriptional state
predicted by the ChIP-seq data set.
Modulation of SOX6 expression regulates adipocyte
differentiation and triglyceride levels
A function for SOX6 in human adipocyte differentiation had not been
reported previously and, in order to test the hypothesis that SOX6
exerts an effect on adipocyte differentiation, we performed siRNA-
mediated SOX6 knockdown experiments with several differentiated
primary humanWharton’s jelly-derivedMSC lines as well as adipose
stromal cell (ASC) lines. Silencing SOX6 expression reduced the
formation of lipid droplets in both human cell lines (MSC-01 and
APOD-01, Fig. 2A,B). These results were concordant with
triglyceride levels measured in the same samples (Fig. 2C,D).
Similar results were obtained in mouse 3T3L1 adipocytes (Fig. S1A),
as well as in additional human ASC and MSC lines (Fig. S1B,
Fig. S2A, Table S2). We also applied the reverse approach by
transfecting a SOX6 expression vector into 3T3L1 preadipocytes and
observed a significant increase in cellular triglyceride levels compared
with the GFP control vector at day 4 of adipogenesis (Fig. S1D).
To confirm that the inhibition of adipogenesis was specifically
due to SOX6 inhibition, we measured the mRNA expression of
Fig. 1. Higher expression of SOX6 in mature adipocytes
derived from SGA MSCs. (A) UCSC genome browser view
of SGA (MSC-01, red) and control (MSC-44, blue) H3K27
acetylation and trimethylation ChIP-seq signals around the
human SOX6 gene locus. Shown are wiggle tracks of
normalized read counts. The two blue arrows indicate the
gene starts of SOX6 and a SOX6 isoform, as well as length
and direction. The green shaded area depicts the promoter
peak. (B) mRNA expression levels of SOX6 in adipocytes
from SGA compared with control as determined by qRT-
PCR. Results are representative of three independent
experiments. Data are shown as mean fold change±s.e.m.
for SOX6 expression relative to that of the MSC-44 cycle 0
sample. A two-way ANOVA analysis was performed to show
a significant difference in the effect of differentiation cycles
(P<0.0001) and MSC lines (P<0.0001) for gene expression
between biological repeats followed by Student’s t-test
(*P<0.05, **P<0.01). (C) SOX6 mRNA expression in an
extended group of SGA (n=8) and control (n=5) MSC lines.
Data are shown as mean fold change±s.e.m. for SOX6
expression relative to control lines at cycle 0. A two-way
ANOVA analysis was performed to show a significant
difference in the effect of differentiation cycles (P=0.0493)
and sample groups (P<0.0001) for gene expression between
MSC lines followed by a Student’s t-test (*P<0.05). (D) SOX6
protein expression is significantly higher in mature
adipocytes from SGA-derived MSCs.
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other SOX family members, such as SOX5, SOX9 and SOX13,
following the siRNA-mediated SOX6 depletion. As shown in
Fig. S2B,C, inhibition of SOX6 did not lead to significant changes
in the expression of other members of the SOX family.
SOX6 enhances adipogenesis by directly regulating the
expression of adipogenic genes
In order to gain mechanistic insights into the effects of SOX6 on
adipogenesis, we examined the expression patterns of key adipocyte
markers in fully differentiated adipocytes. Knockdown of SOX6 led
to a reduction in the expression of genes encoding MEST, FABP4,
FASN, GLUT4 (SLC2A4), PPARγ and C/EBPα in MSC-01 cells
(Fig. 3A-C), in all ASC-derived adipocytes (Fig. S3A,B) and in
mouse 3T3L1 cells (Fig. S4A,B). The transcription factors PPARγ
and C/EBPα are crucial for adipogenesis (Rosen et al., 2002) and
their expression is dependent on that of adipogenic initiation factors
including C/EBPβ and C/EBPδ. Quantitative PCR analyses showed
that the gene encoding C/EBPβ was downregulated by SOX6
depletion inMSC-01 at cycle 0 (Fig. 3B), in ASC lines (Fig. S3A,B,
right panels) and in 3T3L1 preadipocytes (Fig. S4A, right panel).
C/EBPδ expression was not affected in MSC-01 and 3T3L1 cells,
but significantly downregulated in the adult human ASC lines
(Fig. S3A,B, right panels). These findings indicate that SOX6
mediates adipocyte differentiation and lipogenesis by upregulating
the adipogenic signaling cascade, specifically increasing adipocyte
expression of PPARγ, C/EBPα, FABP4 and MEST.
In light of our earlier findings, we further examined whether
SOX6 can directly regulate the expression of MEST and PPARγ by
performing ChIP using preadipocytes (cycle 0/day 0), intermediate
adipocytes (cycle 3/day 4) and mature differentiated adipocytes
(cycle 6/day 8) derived from MSC-01 and 3T3L1 cells. Allowing
one base deviation from the consensus SOX6 binding motif
(WWCAAWG), we identified 17 potential SOX6 binding sites 1 kb
upstream of theMEST gene and designed three sets of primers to test
selected sites (Fig. 3D) in MSC-01 cells. We confirmed that, under
differentiating conditions, SOX6 is enriched at the MEST promoter
Fig. 2. SOX6 downregulation impairs
adipogenesis. (A,B) Human MSC-01 and
APOD-01 cells at different stages of
differentiation. Images are representatives of
three independent experiments.
Quantification of Oil Red O absorption by
spectrophotometry is shown to the right.
Data represent the mean relative
absorbance±s.e.m. compared with siCtrl
cycle/day 0 (n=3, **P<0.01). (C,D) The
amount of total triglycerides in siCtrl-treated or
siSOX6-treated MSC-01 and APOD-01 cells
were measured in triplicate and normalized to
their total protein content in three separate
experiments. Data are shown asmean±s.e.m.
relative to siCtrl cycle/day 0. A two-way
ANOVA was performed to show a significant
difference between time points (P<0.0001)
and between siRNA treatment (P<0.0001 for
MSC-01 and APOD-01) over triglyceride
content followed by a Student’s t-test
(**P<0.01).
952











region (Fig. 3E). Similarly, we observed stronger enrichment of
SOX6 at theMest promoter region in differentiating 3T3L1 cells as
compared with fully differentiated cells at day 8 (Fig. S4C). Our
ChIP analysis also demonstrated that endogenous SOX6 binds to
the PPARG promoter region (Fig. 3E, Fig. S4C), indicating that this
gene is also a direct downstream target of SOX6. In order to further
support the hypothesis that SOX6 directly regulates expression of
the genes encoding MEST and PPARγ by direct promoter
binding, we conducted gene-specific luciferase reporter assays
during the differentiation of 3T3L1 cells. siRNA-mediated SOX6
knockdown reduced both Mest and Pparg reporter gene activity
(Fig. S4D,E).
CpGs within the MEST promoter are hypomethylated in
differentiated adipocytes from SGA neonates and facilitate
the binding of SOX6
Having established a role of SOX6 as an activator of adipogenesis,
we aimed to gain insight into the mechanisms of SOX6 action in the
context of the developmental induction of a propensity to obesity.
We specifically addressed the question of whether potential
synergisms between SOX6 overexpression and other molecular
pathways can be found in Wharton’s jelly-derived MSCs.
There are numerous examples demonstrating an impairment of
transcription factor binding by site-specific CpG methylation (Cho
et al., 2013). In order to investigate whether similar mechanisms
exist for some of the downstream targets of SOX6, we assessed the
methylation status of CpG dinucleotides adjacent to putative SOX6
binding sites within the MEST upstream regulatory region. As
depicted in Fig. 4A, we selected six candidate sites (CpGs A-F) near
theMEST transcriptional start site surrounding three putative SOX6
binding sites and determined their methylation status by
pyrosequencing. We compared five adipocyte cell lines
differentiated from Wharton’s jelly MSCs taken from the control
group and seven corresponding lines from the SGA group. All CpG
sites showed a significant decrease in methylation levels in the SGA
group compared with the controls (Fig. 4B). Hypomethylation
Fig. 3. SOX6 regulates the expression of
key adipogenic genes. (A,B) mRNA
expression levels of genes encoding the
adipocyte markers ADIPOQ, MEST, FABP4,
FASN, GLUT4 and the adipogenic regulators
PPARγ, C/EBPα, C/EBPβ and C/EBPδ were
determined by qRT-PCR in siSOX6-treated
MSC-01 cells in comparison with the control
group (siCtrl) at cycle 6 of adipocyte
differentiation. Data are shown as mean±
s.e.m. of three independent experiments.
**P<0.01, Student’s t-test. (C) Protein
expression of SOX6 and adipogenic markers
in siCtrl-treated and siSOX6-treated MSC-01
cells. (D,E) SOX6 enrichment at theMEST and
PPARG promoters was measured by
ChIP-qPCR at cycles 0, 3 and 6 of adipocyte
differentiation in MSC-01 cells. Data are
shown as mean fold enrichment±s.e.m. of
three independent experiments and were
normalized against IgG enrichment and
against a negative control site (SOX4).
*P<0.05, **P<0.01, Student’s t-test.
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of this region in the SGA group of adipocyte cell lines was
accompanied by increased expression ofMEST (Fig. 4C), indicating
a functional relationship between CpG methylation and gene
expression levels in the two groups.
To examine the mechanistic basis for the above relationship,
we conducted electrophoretic mobility shift assays (EMSAs)
comparing methylated and non-methylated MEST probes covering
the CpG B site next to a SOX6 binding motif. We found that CpG
methylation at this site interferes with SOX6 binding (Fig. 4D),
which might explain the lower expression of MEST in adipocytes
from normal control MSCs and enhanced SOX6 binding in
adipocytes from SGA neonates.
SOX6 inhibits WNT/β-catenin signaling in adipocytes
We observed that SOX6 promotes MEST expression and that SOX6
expression increases during adipocyte differentiation. We therefore
investigated the possibility of SOX6 regulating the WNT signaling
pathway, and showed that ectopic expression of SOX6 attenuates
WNT3A-CM (conditioned medium)-mediated reporter activity
(Fig. 5A). We demonstrated an interaction between β-catenin and
SOX6 by co-immunoprecipitation (Fig. 5B,C). Furthermore,
decreasing SOX6 expression in 3T3L1 cells during differentiation
increased the levels of β-catenin protein (Fig. 5D). Similarly,
treatment of cells with the specific proteasome inhibitor MG132
abolished the SOX6-mediated reduction in total cellular β-catenin
levels and increased protein expression from its transcriptional
target Axin2 (Fig. 5E). These findings indicate that SOX6 depletion
may alleviate suppression of the canonical β-catenin branch of the
WNT signaling pathway by promoting proteasomal degradation of
β-catenin.
SOX6 regulates lipid metabolism in vivo
In order to further establish the role of SOX6 in mediating
adipogenesis in vivo, we investigated the effect of reducing SOX6
levels in C57BL/6 mice using locked nucleic acid antisense
oligonucleotides (LNA ASOs). Sox6-specific ASO treatment was
Fig. 4. CpGs next to SOX6 binding sites
within the MEST upstream regulatory
region are hypomethylated in SGA-
derived differentiated adipocytes and
CpG methylation interferes with SOX6
binding. (A) Map of the human MEST
region next to the transcriptional start site
covering three SOX6 binding sites (open
boxes) surrounded by six CpGs (filled
circles), which were selected for
pyrosequencing. (B) Percentage of CpG
methylation for each of the six individual
CpGs described in A. Genomic locations of
CpGs A-F are given above each bar chart. A
group of control adipocyte lines (n=5) were
compared with those from a group of SGA
lines (n=7). Data are presented as
mean±s.e.m. **P<0.01, *P<0.05, Student’s
t-test. (C) MEST mRNA expression in the
group of SGA (n=7) and control (n=5) MSC
lines as measured by qRT-PCR. Data are
shown as mean fold change±s.e.m. for
MEST expression relative to control lines at
cycle 0. A two-way ANOVA analysis was
performed to show a significant difference in
sample groups (P<0.0001) for gene
expression between the groups of MSC
lines followed by a Student’s t-test
(*P<0.05). (D) EMSA with human
recombinant SOX6 protein at increasing
concentrations and a MEST promoter-
based oligonucleotide encompassing site
CpG B, either methylated or unmethylated
and harboring a putative SOX6 binding site.
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effective in decreasing Sox6 mRNA expression in epididymal
white adipose tissue (EWAT) and significantly decreased the
expression of Pparg, C/ebpa and adiponectin (Fig. 6A). We also
confirmed the Sox6 knockdown in liver and EWAT (Fig. 6B, Fig.
S5A,B). We then measured the lipid profiles and observed that
Sox6 ASO treatment reduced serum and liver triglyceride (Fig. 6C,
D) as well as serum cholesterol levels (Fig. 6E). Serum levels of
several adipokines, including leptin and adiponectin, correlate with
adiposity and imbalances in their secretion may promote obesity-
associated metabolic changes (Maury and Brichard, 2010). Serum
leptin levels were significantly reduced in Sox6 ASO-treated mice
(Fig. 6F), consistent with the known positive correlation of leptin
levels with fat mass (Considine et al., 1996). Serum levels of
adiponectin, however, were not found to be significantly different
in the Sox6 ASO-treated mice compared with the controls
(Fig. 6G), suggesting that adiponectin secretion in the blood
serum does not contribute to the metabolic phenotype of SOX6-
deficient mice.
To identify additional downstream target genes of SOX6 in the
liver, we conducted a gene expression microarray study comparing
livers from the control and Sox6 ASO-treated mice for future
validation of liver-specific functions of SOX6. From the microarray
data set we selected the most significantly expressed genes and
validated their expression levels by qRT-PCR. We confirmed
upregulation of Mknk2 and Upp2 (P≤0.001), as well as significant
downregulation of Pmvk, Fabp5, Immp2l, Nfat5, Dapk1, Ube2e1,
Acss2, Acacb and Fasn (P≤0.001; Fig. S5C).
Loss of Sox6 decreases adipogenesis in zebrafish larvae
To address the potential conservation of Sox6 function in adipocyte
differentiation across vertebrate species, we used zebrafish as an
experimental model. The optical transparency of the zebrafish larva
facilitates the visualization of adipocytes by Nile Red staining in
whole-mount preparations (Flynn et al., 2009). Loss of Sox6
function in zebrafish has previously been shown to disrupt the
differentiation of fast-twitch skeletal muscle fibers, but effects on
Fig. 5. Regulation of the WNT pathway by
SOX6. (A) SOX6 inhibits TOP-FLASH
activity induced by WNT3A-conditioned
medium (WNT3A-CM). HEK293 cells co-
transfected with a GFP or SOX6 expression
plasmid (SOX6 OE) and TOP-FLASH
reporter were incubated with the empty
vector-conditioned medium (EV-CM) or
WNT3A-CM for 16 h, followed by luciferase
assays (left). Data are shown as mean
luminescence (RLU)±s.e.m. compared with
cells in EV-CM. **P<0.01, two-way ANOVA.
To the right is a western blot showing the
expression of SOX6 protein after
transfection. (B,C) Immunoprecipitations
from HEK293 cells with ectopic SOX6
expression (B) or mouse 3T3L1 cells
(C) with SOX6 antibody (left) or β-catenin
antibody (right) show association of
β-catenin with SOX6. Controls were
samples immunoprecipitated with
preimmune mouse or rabbit IgG (IgG). IP,
immunoprecipitating antibody. (D) siRNA-
mediated downregulation of SOX6 leads to
an increase in β-catenin protein expression
in 3T3L1 differentiated adipocytes. (E) The
reduction of β-catenin protein by SOX6 in
3T3L1 adipocytes is based on proteasomal
degradation. Alteration of β-catenin and
AXIN2 protein levels by Sox6 siRNA in the
presence of 2 µM proteasome inhibitor
MG132 versus its absence.
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adipocytes have not been addressed (Jackson et al., 2015). For the
current study, control and sox6 homozygous null mutant larvaewere
stained with Oil Red O (Fig. 7A) or Nile Red (Fig. 7B) to reveal the
localization of adipocyte neutral lipid droplets. Lipid droplets were
reduced both in number and size in the sox6 mutants (Fig. 7A,B).
The number of neutral lipid droplets was decreased in sox6 null
mutants at all developmental stages (Fig. 7C).
DISCUSSION
The process of adipogenesis has been well studied and most
master regulators have been identified. These include PPARγ and
various members of the C/EBP family of transcription factors
(Lefterova et al., 2014). We have described, for the first time, that
the transcription factor SOX6 acts as an activator of adipogenesis
upstream of PPARγ and MEST by direct binding to, and
activation of, their promoters. SOX6 is a group D member of
the SOX family of proteins, which includes SOX5 and SOX13
(Lefebvre et al., 2001), with essential roles in cell differentiation
as demonstrated in studies with myocytes (Hagiwara et al., 2007),
oligodendrocytes (Stolt et al., 2006), chondrocytes (Smits et al.,
2001), neurons (Batista-Brito et al., 2009) and erythroblasts
(Dumitriu et al., 2006). Although a possible role in regulating
insulin secretion in pancreatic β-cells has been reported (Iguchi
et al., 2005), our data suggest a direct metabolic function for
SOX6 in regulating the triglyceride content in white adipose and
liver tissues. This effect is evolutionarily conserved among
vertebrates, as our data from sox6−/− zebrafish show.
Themechanismof actionmay differ in a tissue-specificmanner, but
in adipocytes, in addition to the direct regulation ofPPARγ andC/EBP
expression, we showed that SOX6 inhibitsWNT signaling by binding
to β-catenin, potentially leading to its degradation (Fig. 8). Our data
from differentiated adipocytes reveal that this interaction involves
proteasomal degradation of β-catenin with subsequent inhibition of
β-catenin/T-cell factor (TCF) signaling. As the WNT pathway is
known to inhibit adipogenesis (Ross et al., 2000; Kennell and
MacDougald, 2005), SOX6 therefore counteracts this negative
influence and promotes adipocyte differentiation. However, the
interaction with β-catenin is not the only way in which SOX6 can act
Fig. 6. Decreased lipid levels in mice
following Sox6 ASO treatment. (A) Mice
(n=9 animals per group) on a chow diet were
treated with control or Sox6 ASO (50 mg/kg/
week) by i.p. injection for a week. mRNA
expression ofSox6 and selected adipogenic
genes in EWAT after ASO treatment.
(B) mRNA expression of Sox6 in the liver of
ASO-treated mice. (C-E) Serum and liver
triglyceride as well as serum cholesterol
levels are reduced in mice treated with Sox6
ASOs. (F,G) Serum levels of leptin and
adiponectin levels in control and Sox6
ASO-treated mice. Data are presented as
mean±s.e.m. **P<0.01, *P<0.05, Student’s
t-test.
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upon WNT signaling. One of the key molecular associates of
adipocyte size is the geneMEST and we identified a strong effect of
SOX6 depletion onMESTexpression levels, which can be explained
by our data revealing direct binding of SOX6 to theMEST promoter.
MEST has been reported to inhibit the WNT/β-catenin signaling
pathway by sequestering β-catenin (Li et al., 2014) and through
glycosylation of LRP6 (Jung et al., 2011). MEST (PEG1) is an
imprinted gene that is expressed from the paternal allele (Kamei et al.,
2007), and probable developmental functions of MEST could
complement those of SOX6.
At present, we do not understand which factors promote SOX6
upregulation in SGA-derived adipocytes, apart from the strong
association with hyperacetylated histones. But higher SOX6
expression levels in adipocytes from SGA individuals may
synergize with MEST hypomethylation at CpGs found next to
putative SOX6 binding sites. Decreased CpGmethylation within the
MEST promoter may facilitate SOX6 binding, thereby enhancing
MEST expression, which in turn will stimulate lipogenesis and
adipocyte growth. This model is supported by our EMSA data
demonstrating impaired SOX6 binding to aMEST promoter template
with adjacent CpG methylation. Our findings therefore extend
published observations that obesity significantly associates with
decreased methylation levels at theMEST gene (Soubry et al., 2015),
that MEST hypomethylation is linked to metabolic programming in
offspring with a background in gestational diabetes (El Hajj et al.,
2013), and that there is an inverse relationship between MEST CpG
methylation levels and body composition measures, such as waist
circumference and body mass index (Carless et al., 2013).
We previously published observations of significant molecular
changes inWharton’s jelly-derivedMSCs from SGA infants prior to
(Sukarieh et al., 2014) and post (Joseph et al., 2015) adipocyte
differentiation. Given its evolutionary importance and demonstration
inmultiple species (Hanson andGluckman, 2014), it seems probable
that multiple molecular pathways operate to predispose individuals
with a history of suboptimal early-life conditions to later increased
metabolic disease risk. However, our study cannot conclusively
prove a direct role for SOX6 in directing the fetal origins of human
obesity but, in concertwith other likelymechanisms, such as its direct
effects on PPARγ expression and WNT signaling, SOX6 may be
considered a key candidate in such processes.
The basic functions of SOX6 in adipogenesis are conserved
between humans and other vertebrates, as shown by our cell line
(mouse 3T3L1) and in vivo (mouse and zebrafish) data. Future
research will address in more detail the mechanisms underlying the
Fig. 7. sox6 mutant zebrafish larvae
exhibit decreased adipogenesis.
(A) Oil Red O staining reveals localization
of adipocyte neutral lipid droplets in
larvae at 23 days post fertilization (dpf ).
The arrows indicate the localization of
adipocytes. The number and the size of
neutral lipid droplets are decreased in
sox6 mutants. Swim bladder (sb) and
intestine (in) are indicated. Anterior is to
the right and dorsal at the top in all
images. Error bars represent s.d.; sibling
n=4, mutant n=4; **P<0.01, two-tailed
unpaired Student’s t-test. (B) Nile Red
staining reveals that adipocyte lipid
droplets are decreased in number and in
size within the viscera of sox6 mutant
larvae at 25 dpf. Bright-field (upper panel)
and corresponding fluorescence images
(lower panel) are shown. Swim bladder
(sb) and gall bladder (G) are indicated.
The arrows indicate the localization of
adipocytes (dotted line). (C) Live larvae at
13, 15 and 25 dpf were stained with Nile
Red. The number of lipid droplets is
decreased in sox6 mutant larvae at all
these developmental stages. Error bars
represent s.d.; sibling n=4, mutant n=4;
*P<0.05, two-tailed unpaired Student’s
t-test.
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dysregulation of SOX6 expression in the context of fetal growth
restriction.
MATERIALS AND METHODS
Clinical populations and sample collection
Fresh UCs were obtained from children born at the National University
Hospital (NUH), Singapore. Institutional Review Board (IRB) approval by
the National University Health System (NUHS) was granted before cord
collection. Prior written parental consent to participate in this study was
obtained and ethical approval obtained by the Domain Specific Review
Board (DSRB, # 2011/00355) of NUH.
Collection and establishment of human ASC lines
Prior written consent to participate in this study was obtained and ethical
approval was granted by the Domain Specific Review Board (DSRB, #2013/
00171) of NUH. Human subcutaneous white adipose tissue (WAT) was
obtained from twomorbidlyobese patientswho underwent either laparoscopic
sleeve gastrectomy or Roux-en-Y gastric bypass (Table S1). The ASC lines
APOD-01 and APOD-02 were established according to standard procedures.
Briefly, less than 1 g WAT was digested with 1 mg/ml collagenase type IA
(Sigma C9891-1G) in 20 mg/ml bovine serum albumin (BSA) for 90 min at
37°C with shaking (120 rpm). Cell pellets were collected by centrifugation at
800 g for 10 min, and then resuspended in 9 ml red blood cell (RBC) lysis
buffer for 10 min. Cells were filtered through a 100 µm cell strainer and
resuspended in growth medium comprising Dulbecco’s modified Eagle’s
medium (DMEM)/F-12 GlutaMAX (Gibco) containing 20% fetal bovine
serum (FBS) (Gibco 16000), 1% penicillin/streptomycin (Gibco 15140).
Assessment of fetal growth characteristics
Fetal growth characteristics were assessed by published methods (Sukarieh
et al., 2014; Joseph et al., 2015). Briefly, the SGA condition was diagnosed
by ultrasonography and determined as growth between the fifth and tenth
percentile when compared with a control reference population. Standard
scans were conducted by trained ultrasonographers, using ultrasound
machines (Aloka SSD- 4000, GE Voluson E8).
Preparation and propagation of MSCs from human UC
The preparation and full characterization of the primary MSC isolates used
in this study has been reported (Fong et al., 2010; Sukarieh et al., 2014;
Joseph et al., 2015). A brief overview of the characteristics of all primary
cell isolates used here is provided in Table S2. For all experiments described,
the primary cell lines were passaged up to ten times.
Adipocyte differentiation
Wharton’s jelly MSCs
The differentiation of MSCs is described by Joseph et al. (2015).
Human ASCs
Cells were plated in 3 cm or 6 cm dishes coated with 0.2% gelatin and
grown in growth medium [DMEM/F-12 GlutaMAX, 20% FBS,
antibiotic/antimycotic mixture (Gibco 15240-062)]. Two days after
reaching confluence (day 0), the cells were stimulated to differentiate
by culturing them in IBMX induction medium comprising DMEM/F-12
GlutaMAX, 10% FBS, supplemented with 0.5 mM
isobutylmethylxanthine (IBMX, Sigma I-7018), 1 µM dexamethasone
(Sigma D-4902), 200 µM indomethacine (Sigma I-8280) and 58 μg/ml
insulin (bovine, Sigma I-5500), for 1 week with replacement by fresh
medium every 2 days. After 1 week, the IBMX induction medium was
replaced with insulin medium comprising DMEM/F-12 GlutaMAX, 10%
FBS, supplemented with 0.01 mg/ml insulin. The insulin medium was
changed every 2 days. The siRNA knockdown was performed before
differentiation and every 4 days during differentiation.
Mouse 3T3L1 cells
Cells were obtained from ATCC and plated in 3 cm or 6 cm dishes coated
with 0.2% gelatin and grown in growth medium (DMEM high glucose
with 2 mM L-glutamine, 10% FBS, antibiotic/antimycotic mixture) and
allowed to grow to confluence for 2-3 days. The cells were then treated
with induction medium comprising DMEM high glucose with 2 mM
L-glutamine, 10% FBS, supplemented with 0.5 mM IBMX, 1 µM
dexamethasone, 0.01 mg/ml insulin (day 0) for 48 h. After 48 h, the
induction medium was replaced with insulin medium comprising DMEM
high glucose with 2 mM L-glutamine, 10% FBS, 0.01 mg/ml insulin. The
insulin medium was changed every 2 days.
Oil Red O staining
Adipogenesis was quantified by Oil Red O staining following standard
procedures. The adipogenic cultures in 3 cm dishes were washed with PBS
and fixed with 10% formaldehyde for 30-60 min at room temperature. Oil
Red O stock solution [0.3 g powder (Sigma O0625) in 100 ml isopropanol]
was mixed 3:2 with deionized water and left at room temperature for 10 min
before filtering. The Oil Red O solution was added to the dishes for 10 min
at room temperature.
For whole-mount zebrafish staining, larvae were fixed with 4%
paraformaldehyde (PFA), rinsed with PBT (PBS with 0.5% Tween 20),
and stained with the filtered Oil Red O solution for 15 min at room
temperature. Stained larvae were rinsed three times with PBT and twice with
60% isopropanol for 5 min each, then briefly rinsed with PBT and refixed
with 4% PFA for 10 min. Finally, the larvae were mounted in 3%
methylcellulose and imaged using an AxioCam HRc mounted on an Axio
Imager M2 (Zeiss).
Nile Red staining
Nile Red (Wako 144-0811) was dissolved in acetone at 1.25 mg/ml and kept
at −20°C in the dark. Live zebrafish were placed in egg water containing
0.5 μg/ml Nile Red for 30 min in the dark. Zebrafish were then anesthetized
using tricaine (Sigma-AldrichMS-222) andmounted in 3%methylcellulose
for imaging as above.
Fig. 8. Model of SOX6 regulation of adipogenesis. SOX6 activates
adipogenesis by directly promoting the expression of C/EBP proteins and
PPARγ. In addition, SOX6 binds to the MEST promoter to activate its
expression, which in response inhibits WNT signaling. SOX6 also directly
binds to β-catenin, leading to its degradation, which further blocks WNT
signaling, promoting adipocyte differentiation.
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ChIP-seq of histone H3K27 acetylation and methylation and
bioinformatics analysis
All procedures for the ChIP-seq study, including all analytical steps, were as
published (Joseph et al., 2015). The ChIP-seq data are available at the GEO
repository (GSE64697).
ChIP
To preserve protein-DNA complexes, 1% formaldehyde was added to the
cells for 10 min at room temperature. The cross-linking reactions were
stopped by adding 125 mM glycine for 5 min and cells were incubated in
SDS lysis buffer and sonicated (Diagenode Bioruptor) for 12 min.
Chromatin fragments were precleared with protein A-Sepharose beads
(Invitrogen 10-1142) and BSA at 4°C for 2 h prior to immunoprecipitation
with 5 μg SOX6 antibody (Abcam ab30455) or 5 μg rabbit IgG control
antibody (Santa Cruz sc-2027) overnight at 4°C. After washing and eluting
the Sepharose beads with SDS elution buffer, the cross-links were reversed
at 65°C overnight. The QIAquick PCR Purification Kit (Qiagen) was used
for sample purification following the manufacturer’s instructions.
Quantitative ChIP-PCR analysis
For the data shown in Fig. 3E,MEST and PPARG promoter-specific primers
(Table S3) were used to analyze ChIP enrichment using the ABI 7900
system (PerkinElmer).
Co-immunoprecipitation assay
Cells were washed with ice-cold PBS and then lysed in 50 mM Tris (pH 8),
150 mM NaCl, 0.5% NP40, 0.5% deoxycholic acid, 0.005% SDS and
protease inhibitors for 30 min on ice. Samples were centrifuged and the
supernatants incubated with anti-SOX6 (Abcam ab125196; used at 2 μg/ml
lysate), anti-β-catenin (BD Transduction Laboratories 610153; used at 2 μg/
ml lysate), or rabbit IgG (Santa Cruz sc-2027; used at 2 μg/ml lysate) or
mouse IgG (Santa Cruz sc-2025; used at 2 μg/ml lysate) control antibodies
overnight at 4°C and with protein G-Sepharose beads (Invitrogen 10-1243)
for 2 h. Beads were washed up to four times with 500 μl PBS, 0.1% Tween
20. SDS sample buffer was used to elute all bound proteins, which were then
separated by SDS-PAGE followed by immunoblotting with the specific
antibodies stated.
RNA extraction
Cells were spun down [1000 rpm (207 g), 3 min] in 1.7 ml tubes and
resuspended in 0.5 ml TRIzol reagent (Life Technologies 15596-026).
Samples were snap-frozen on dry ice and stored at−80°C. RNAwas isolated
and purified using the RNeasy Mini Kit (Qiagen 74106) following the
manufacturer’s protocol.
Quantitative real-time PCR
For qRT-PCR, total RNA (1-2 µg) was reverse transcribed using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). cDNA
samples were subjected to real-time PCR analysis (in triplicate) with gene-
specific primers (Table S3) using an ABI 7900 HT Sequence Detection
System (Applied Biosystems). Target gene expression levels were
normalized to endogenous control genes (GAPDH or Ppia) and presented
relative to the controls.
Animal studies
Rodents
C57BL/6NTac mice were purchased from BRC, A*STAR. All experimental
procedures were approved by the Institutional Animal Care and Use
Committee (IACUC). All mice were monitored daily for signs of morbidity.
Whole blood was collected by cardiac puncture. For tissue collection, the
mice were sacrificed according to IACUC guidelines, and EWAT and liver
were collected for analysis.
Zebrafish
A 14 h light/10 h dark cycle at 28°C in the AVA (Singapore) certificated
IMCB Zebrafish Facility was employed for the maintenance of adult fish.
The zebrafish strain used was Sox6i292 (Jackson et al., 2015).
ASO in vivo administration
Lyophilized LNA ASOs were produced according to Exiqon proprietary
design software and dissolved in sterile water. The sequences (5′-3′) for the
ASOs used are: negative control, AACACGTCTATACGC; SOX6 sequence,
TCTAGGTGGATTTTGC. ASOs were then diluted in saline to the desired
concentration for dosing mice and sterilized through a 0.2 μm filter. Mice
were anesthetized with Avertin before ASOs were delivered via
intraperitoneal (i.p.) injection at 50 mg/kg per week. After 1 week, mice
were sacrificed for blood and tissue collection.
Quantification of triglyceride content
Total soluble lipids from adipocytes differentiated from MSCs and 3T3L1
cells were extracted using the buffer provided with the commercial
Adipogenesis Detection Kit (Abcam ab102513) and samples stored at
−80°C until analysis. Triglycerides were quantified using the Triglyceride
Quantification Kit (Abcam ab65336) as per the manufacturer’s instructions.
Quantification of cholesterol
Whole blood was obtained frommice by cardiac puncture. Blood was stored
in Sarstedt S-Monovette tubes containing serum gel. Serumwas obtained by
centrifuging the tubes at 10,000 g at room temperature for 10 min. Liver
samples from mice were snap-frozen and kept at −80°C until analysis. Total
cholesterol was measured using the Cholesterol/Cholesteryl Ester
Quantification Kit (Abcam ab65359) using a colorimetric method as per
the manufacturer’s instructions.
Quantification of leptin and adiponectin
Serum levels of leptin and adiponectin were determined using ELISA, as per
the manufacturer’s instructions (R&D Systems, MOB00, MRP300).
Western blotting
Differentiated adipocytes were harvested in RIPA buffer (50 mM Tris-HCl
pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 0.1% SDS). Membranes
were probed with primary antibodies specific to SOX6 (Abcam ab125196;
1:1000), MEST (Abcam ab151564; 1:1000), β-catenin (BD Transduction
Labs 610153; 1:1000), AXIN2 (Abcam ab109307; 1:500), PPARγ (Santa
Cruz sc7196; 1:1000), C/EBPα (Santa Cruz sc61; 1:1000), FABP4 (Abcam
ab66682; 1:1000) and the endogenous control protein β-actin (Sigma
A1978; 1:10,000). To inhibit proteasome-mediated protein degradation,
2 µMMG132 (Sigma C2211) was added to the cells. The LI-COROdyssey
2.1 system was used for signal detection (secondary antibodies LI-COR
926-32211, 926-68020) and band analysis.
SOX6 siRNA knockdown studies
SOX6was knocked down before differentiation and before each cycle of the
adipocyte induction process in insulin medium using ON-TARGETplus
Human SOX6 siRNA SMARTpool (Dharmacon L-015101-01-0050), ON-
TARGETplus Mouse Sox6 siRNA SMARTpool (Dharmacon L0442910-
01-0050) or ON-TARGETplus Non-targeting Pool siRNA (Dharmacon D-
001810-10-50) at a final concentration of 100 nM. Transfections were
conducted using Lipofectamine RNAiMAX (Invitrogen 13778150).
SOX6 overexpression study
For the overexpression of SOX6, mouse 3T3L1 cells were transfected using
Lipofectamine LTX (Invitrogen) with 2.5 µg GFP-tagged plasmid
containing the mouse Sox6 gene (MG227129; Origene Technologies) in
6 cm dishes. This transient transfection was performed before differentiation
and every 2 days during differentiation.
Luciferase reporter assay
For the WNT activity reporter assay, HEK293 cells were cultured in growth
medium (DMEM high glucose with 2 mM L-glutamine, 10% FBS,
antibiotic/antimycotic mixture). Cells seeded in 6-well plates were co-
transfected with 1 μg SuperTOP-FLASH (Addgene plasmid #12456),
100 ng pTK-Renilla luciferase (Promega E2241) and 1.5 μg GFP-tagged
plasmid containing the human SOX6 gene (Origene Technologies
RG211525). For the PPARγ reporter assay, 3T3L1 cells were co-
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transfected with 1 μg PPRE-X3-TK-luc (Addgene plasmid #1015) and
100 ng pTK-Renilla luciferase. All assays were conducted following the
Dual-Luciferase Assay protocols (Promega E1910). TOP-FLASH activity
was normalized against Renilla luciferase readout. For the MEST reporter
assay, 3T3L1 cells were co-transfected with 1 μg custom-made GLuc_ON
MEST promoter reporter using pEZX-PG04 vector (GeneCopoeia
MPRM26666-PG04). Assays were performed according to the Secrete-
Pair Gaussia Luciferase Dual Assay Kit (GeneCopoeia SPDA-D010).
Secreted alkaline phosphatase luciferase activity was used to normalize
Gaussia luciferase (GLuc)-MEST promoter activity.
Pyrosequencing
Genomic DNAwas prepared and converted with bisulfite using the EpiTect
Bisulfite Kit (Qiagen) according to the manufacturer’s recommendations.
Pyrosequencing was performed using a PyroMark Q24 machine (Qiagen) in
10-15 µl PCR product in a standard reaction volume. PCR and sequencing
primers are provided in Table S3.
EMSA
EMSAwas performed using the Odyssey Infrared EMSA Kit (LI-COR 829-
07910). Varying concentrations of human recombinant SOX6 protein
(Origene TP312046) were incubated for 20 min at room temperature with a
synthetic SOX6 oligonucleotide 5′ end-labeled with IRDye 700 (Integrated
DNA Technologies) with or without 5-methyl-dC modification at the CpG
motif (double stranded, 5′-TTATTCTCTTTATCCAATGCCGGAGGCTAT-
3′) and a binding mix following the manufacturer’s protocol. Separation of
reaction products was performed on a 6% non-denaturing polyacrylamide gel
in 0.5× cold TBE buffer (pH 8).
Gene expression microarray
Differential gene expression levels in liver tissue comparing SOX6 and
control ASOs were determined by employing HumanHT-12 v4 Expression
BeadChip technology (Illumina BD-103-0204). The Illumina iScan system
was used for scanning the arrays followed by data extraction using Illumina
Genome Bead Studio Software. After background subtraction, P-values
<0.05 and NBEADS >3 using the R program were determined. The data
were further analyzed with Arraystudio (Omicsoft). Probes that passed
signal detected P<0.05 in all the samples were retained. Log2 transformation
(intensity values <1 censored to 0) was performed followed by quantile
normalization. One-way ANOVA (∼t-test) was performed to determine
differential gene expression. Gene expression microarray data are available
at GEO under accession number GSE70300.
Statistics
Data are generally presented as mean±s.e.m. Comparisons between groups
and time courses [e.g. the adipogenesis differentiation assays involving
different stages (cycles)] were analyzed by repeated measures analysis of
variance (ANOVA). All normal comparisons between groups were assessed
using Student’s t-test, with P<0.05 considered significant.
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